

Novel Coronavirus (COVID-19) Vaccine Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/NBAD97F3CB94EN.html>

Date: March 2022

Pages: 107

Price: US\$ 3,250.00 (Single User License)

ID: NBAD97F3CB94EN

Abstracts

This report contains market size and forecasts of Novel Coronavirus (COVID-19) Vaccine in Global, including the following market information:

Global Novel Coronavirus (COVID-19) Vaccine Market Size 2023-2028, (\$ millions)

The global Novel Coronavirus (COVID-19) Vaccine market is projected to reach US\$ million by 2028.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Novel Coronavirus (COVID-19) Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Novel Coronavirus (COVID-19) Vaccine Market, by Type, 2023-2028 (\$ millions)

Global Novel Coronavirus (COVID-19) Vaccine Market Segment Percentages, by Type

DNA

RNA

Others

Global Novel Coronavirus (COVID-19) Vaccine Market, by Application, 2023-2028 (\$ millions)

Global Novel Coronavirus (COVID-19) Vaccine Market Segment Percentages, by Application

Mild Symptom Patient

Critically Ill Patient

Global Novel Coronavirus (COVID-19) Vaccine Market, By Region and Country, 2023-2028 (\$ Millions)

Global Novel Coronavirus (COVID-19) Vaccine Market Segment Percentages, By Region and Country

United States

Europe

Asia

China

Rest of World

Competitor Analysis

The report also provides analysis of leading market participants including:

Further, the report presents profiles of competitors in the market, key players include:

Inovio Pharmaceuticals

Takis Biotech (Evvivax)

Zydus Cadila

Codagenix, Inc.

GeoVax, Inc.

Bravovax

Janssen Pharmaceutical Companies

Altimune

Vaxart

CanSino Biologics

ExpreS2ion Biotechnologies ApS

Clover Biopharmaceuticals

GSK

Vaxil Bio Ltd.

Generex

Novavax, Inc.

Sanofi Pasteur

Baylor

iBio, Inc.

Moderna, Inc.

Curevac

ImmunoPrecise

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Novel Coronavirus (COVID-19) Vaccine Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Novel Coronavirus (COVID-19) Vaccine Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL NOVEL CORONAVIRUS (COVID-19) VACCINE OVERALL MARKET SIZE

- 2.1 Global Novel Coronavirus (COVID-19) Vaccine Market Size: 2022 VS 2028
- 2.2 Global Novel Coronavirus (COVID-19) Vaccine Market Size, Prospects & Forecasts: 2022-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Key Novel Coronavirus (COVID-19) Vaccine Players in Global Market
- 3.2 Global Companies Novel Coronavirus (COVID-19) Vaccine Product & Technology

4 PLAYERS PROFILES

- 4.1 Inovio Pharmaceuticals
 - 4.1.1 Inovio Pharmaceuticals Corporate Summary
 - 4.1.2 Inovio Pharmaceuticals Business Overview
 - 4.1.3 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology

- 4.1.4 Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.2 Takis Biotech (Evvivax)
 - 4.2.1 Takis Biotech (Evvivax) Corporate Summary
 - 4.2.2 Takis Biotech (Evvivax) Business Overview
 - 4.2.3 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.2.4 Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.3 Zydus Cadila
 - 4.3.1 Zydus Cadila Corporate Summary
 - 4.3.2 Zydus Cadila Business Overview
 - 4.3.3 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.3.4 Zydus Cadila Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.4 Codagenix, Inc.
 - 4.4.1 Codagenix, Inc. Corporate Summary
 - 4.4.2 Codagenix, Inc. Business Overview
 - 4.4.3 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.4.4 Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.5 GeoVax, Inc.
 - 4.5.1 GeoVax, Inc. Corporate Summary
 - 4.5.2 GeoVax, Inc. Business Overview
 - 4.5.3 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.5.4 GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.6 Bravovax
 - 4.6.1 Bravovax Corporate Summary
 - 4.6.2 Bravovax Business Overview
 - 4.6.3 Bravovax Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.6.4 Bravovax Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.7 Janssen Pharmaceutical Companies
 - 4.7.1 Janssen Pharmaceutical Companies Corporate Summary
 - 4.7.2 Janssen Pharmaceutical Companies Business Overview
 - 4.7.3 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.7.4 Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.8 Altimune

- 4.8.1 Altimmune Corporate Summary
- 4.8.2 Altimmune Business Overview
- 4.8.3 Altimmune Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
- 4.8.4 Altimmune Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.9 Vaxart
 - 4.9.1 Vaxart Corporate Summary
 - 4.9.2 Vaxart Business Overview
 - 4.9.3 Vaxart Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.9.4 Vaxart Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.10 CanSino Biologics
 - 4.10.1 CanSino Biologics Corporate Summary
 - 4.10.2 CanSino Biologics Business Overview
 - 4.10.3 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.10.4 CanSino Biologics Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.11 ExpreS2ion Biotechnologies ApS
 - 4.11.1 ExpreS2ion Biotechnologies ApS Corporate Summary
 - 4.11.2 ExpreS2ion Biotechnologies ApS Business Overview
 - 4.11.3 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.11.4 ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.12 Clover Biopharmaceuticals
 - 4.12.1 Clover Biopharmaceuticals Corporate Summary
 - 4.12.2 Clover Biopharmaceuticals Business Overview
 - 4.12.3 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.12.4 Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.13 GSK
 - 4.13.1 GSK Corporate Summary
 - 4.13.2 GSK Business Overview
 - 4.13.3 GSK Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.13.4 GSK Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.14 Vaxil Bio Ltd.
 - 4.14.1 Vaxil Bio Ltd. Corporate Summary
 - 4.14.2 Vaxil Bio Ltd. Business Overview
 - 4.14.3 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product Offerings &

Technology

4.14.4 Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans

4.15 Generex

4.15.1 Generex Corporate Summary

4.15.2 Generex Business Overview

4.15.3 Generex Novel Coronavirus (COVID-19) Vaccine Product Offerings &

Technology

4.15.4 Generex Novel Coronavirus (COVID-19) Vaccine R&D, and Plans

4.16 Novavax, Inc.

4.16.1 Novavax, Inc. Corporate Summary

4.16.2 Novavax, Inc. Business Overview

4.16.3 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings &

Technology

4.16.4 Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans

4.17 Sanofi Pasteur

4.17.1 Sanofi Pasteur Corporate Summary

4.17.2 Sanofi Pasteur Business Overview

4.17.3 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product Offerings &

Technology

4.17.4 Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine R&D, and Plans

4.18 Baylor

4.18.1 Baylor Corporate Summary

4.18.2 Baylor Business Overview

4.18.3 Baylor Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology

4.18.4 Baylor Novel Coronavirus (COVID-19) Vaccine R&D, and Plans

4.19 iBio, Inc.

4.19.1 iBio, Inc. Corporate Summary

4.19.2 iBio, Inc. Business Overview

4.19.3 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings &

Technology

4.19.4 iBio, Inc. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans

4.20 Moderna, Inc.

4.20.1 Moderna, Inc. Corporate Summary

4.20.2 Moderna, Inc. Business Overview

4.20.3 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings &

Technology

4.20.4 Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine R&D, and Plans

4.21 Curevac

4.21.1 Curevac Corporate Summary

- 4.21.2 Curevac Business Overview
- 4.21.3 Curevac Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
- 4.21.4 Curevac Novel Coronavirus (COVID-19) Vaccine R&D, and Plans
- 4.22 ImmunoPrecise
 - 4.22.1 ImmunoPrecise Corporate Summary
 - 4.22.2 ImmunoPrecise Business Overview
 - 4.22.3 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product Offerings & Technology
 - 4.22.4 ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine R&D, and Plans

5 SIGHTS BY REGION

- 5.1 By Region - Global Novel Coronavirus (COVID-19) Vaccine Market Size, 2023 & 2028
- 5.2 By Region - Global Novel Coronavirus (COVID-19) Vaccine Revenue, (2023-2028)
- 5.3 United States
 - 5.3.1 Key Players of Novel Coronavirus (COVID-19) Vaccine in United States
 - 5.3.2 United States Novel Coronavirus (COVID-19) Vaccine Development Current Situation and Forecast
- 5.4 Europe
 - 5.4.1 Key Players of Novel Coronavirus (COVID-19) Vaccine in Europe
 - 5.4.2 Europe Novel Coronavirus (COVID-19) Vaccine Development Current Situation and Forecast
- 5.5 China
 - 5.5.1 Key Players of Novel Coronavirus (COVID-19) Vaccine in China
 - 5.5.2 China Novel Coronavirus (COVID-19) Vaccine Development Current Situation and Forecast
- 5.6 Rest of World

6 SIGHTS BY PRODUCT

- 6.1 by Type - Global Novel Coronavirus (COVID-19) Vaccine Market Size Markets, 2023 & 2028
- 6.2 DNA
- 6.3 RNA
- 6.4 Others

7 SIGHTS BY APPLICATION

7.1 By Application - Global Novel Coronavirus (COVID-19) Vaccine Market Size, 2023 & 2028

7.2 Mild Symptom Patient

7.3 Critically Ill Patient

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Novel Coronavirus (COVID-19) Vaccine Market Opportunities & Trends in Global Market

Table 2. Novel Coronavirus (COVID-19) Vaccine Market Drivers in Global Market

Table 3. Novel Coronavirus (COVID-19) Vaccine Market Restraints in Global Market

Table 4. Key Players of Novel Coronavirus (COVID-19) Vaccine in Global Market

Table 5. Global Companies Novel Coronavirus (COVID-19) Vaccine Product & Technology

Table 6. Inovio Pharmaceuticals Corporate Summary

Table 7. Inovio Pharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 8. Takis Biotech (Evvivax) Corporate Summary

Table 9. Takis Biotech (Evvivax) Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 10. Zydus Cadila Corporate Summary

Table 11. Zydus Cadila Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 12. Codagenix, Inc. Corporate Summary

Table 13. Codagenix, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 14. GeoVax, Inc. Corporate Summary

Table 15. GeoVax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 16. Bravovax Corporate Summary

Table 17. Bravovax Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 18. Janssen Pharmaceutical Companies Corporate Summary

Table 19. Janssen Pharmaceutical Companies Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 20. Altimmune Corporate Summary

Table 21. Altimmune Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 22. Vaxart Corporate Summary

Table 23. Vaxart Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 24. CanSino Biologics Corporate Summary

Table 25. CanSino Biologics Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 26. ExpreS2ion Biotechnologies ApS Corporate Summary

Table 27. ExpreS2ion Biotechnologies ApS Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 28. Clover Biopharmaceuticals Corporate Summary

Table 29. Clover Biopharmaceuticals Novel Coronavirus (COVID-19) Vaccine Product

Offerings

Table 30. GSK Corporate Summary

Table 31. GSK Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 32. Vaxil Bio Ltd. Corporate Summary

Table 33. Vaxil Bio Ltd. Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 34. Generex Corporate Summary

Table 35. Generex Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 36. Novavax, Inc. Corporate Summary

Table 37. Novavax, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 38. Sanofi Pasteur Corporate Summary

Table 39. Sanofi Pasteur Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 40. Baylor Corporate Summary

Table 41. Baylor Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 42. iBio, Inc. Corporate Summary

Table 43. iBio, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 44. Moderna, Inc. Corporate Summary

Table 45. Moderna, Inc. Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 46. Curevac Corporate Summary

Table 47. Curevac Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 48. ImmunoPrecise Corporate Summary

Table 49. ImmunoPrecise Novel Coronavirus (COVID-19) Vaccine Product Offerings

Table 50. By Region– Global Novel Coronavirus (COVID-19) Vaccine Revenue, (US\$, Mn), 2023 & 2028

Table 51. By Region - Global Novel Coronavirus (COVID-19) Vaccine Revenue, (US\$, Mn), 2023-2028

Table 52. By Type – Global Novel Coronavirus (COVID-19) Vaccine Market Size, (US\$, Mn), 2023 & 2028

Table 53. By Application– Global Novel Coronavirus (COVID-19) Vaccine Market Size, (US\$, Mn), 2023 & 2028

List Of Figures

LIST OF FIGURES

- Figure 1. Novel Coronavirus (COVID-19) Vaccine Segment by Type in 2021
- Figure 2. Novel Coronavirus (COVID-19) Vaccine Segment by Application in 2021
- Figure 3. Global Novel Coronavirus (COVID-19) Vaccine Market Overview: 2022
- Figure 4. Key Caveats
- Figure 5. Global Novel Coronavirus (COVID-19) Vaccine Market Size: 2022 VS 2028 (US\$, Mn)
- Figure 6. Global Novel Coronavirus (COVID-19) Vaccine Revenue, 2017-2028 (US\$, Mn)
- Figure 7. By Region - Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share, 2023-2028
- Figure 8. By Type - Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share, 2023-2028
- Figure 9. By Application - Global Novel Coronavirus (COVID-19) Vaccine Revenue Market Share, 2023-2028

I would like to order

Product name: Novel Coronavirus (COVID-19) Vaccine Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/NBAD97F3CB94EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NBAD97F3CB94EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970